WallStreetZenWallStreetZen

NASDAQ: PRLD
Prelude Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PRLD

Based on 2 analysts offering 12 month price targets for Prelude Therapeutics Inc

Min Forecast
$4.00+300%
Avg Forecast
$4.50+350%
Max Forecast
$5.00+400%

Should I buy or sell PRLD stock?

Based on 2 analysts offering ratings for Prelude Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PRLD's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates PRLD as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PRLD stock forecasts and price targets.

PRLD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-05
lockedlocked$00.00+00.00%2025-04-29

1 of 1

Forecast return on equity

Is PRLD forecast to generate an efficient return?

Company
-53.63%
Industry
138.99%
Market
90.49%
PRLD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PRLD forecast to generate an efficient return on assets?

Company
-39.17%
Industry
36.84%
PRLD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PRLD earnings per share forecast

What is PRLD's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.64
Avg 2 year Forecast
-$1.36
Avg 3 year Forecast
-$1.05

PRLD revenue forecast

What is PRLD's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$35.5M

PRLD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PRLD$1.00$4.50+350.00%Buy
IKNA$1.16N/AN/A
PDSB$1.27$10.00+687.40%Strong Buy
ACET$0.67$7.00+947.90%Strong Buy
IMMX$1.98$7.00+253.54%Buy
View Top Biotech Stocks

Prelude Therapeutics Stock Forecast FAQ

Is Prelude Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: PRLD) stock is to Buy PRLD stock.

Out of 2 analysts, 0 (0%) are recommending PRLD as a Strong Buy, 2 (100%) are recommending PRLD as a Buy, 0 (0%) are recommending PRLD as a Hold, 0 (0%) are recommending PRLD as a Sell, and 0 (0%) are recommending PRLD as a Strong Sell.

If you're new to stock investing, here's how to buy Prelude Therapeutics stock.

What is PRLD's earnings growth forecast for 2025-2027?

(NASDAQ: PRLD) Prelude Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.21%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.88%.

Prelude Therapeutics's earnings in 2025 is -$127,827,000.On average, 2 Wall Street analysts forecast PRLD's earnings for 2025 to be -$92,312,886, with the lowest PRLD earnings forecast at -$94,853,608, and the highest PRLD earnings forecast at -$89,772,165. On average, 2 Wall Street analysts forecast PRLD's earnings for 2026 to be -$76,503,952, with the lowest PRLD earnings forecast at -$84,690,722, and the highest PRLD earnings forecast at -$68,317,182.

In 2027, PRLD is forecast to generate -$59,283,505 in earnings, with the lowest earnings forecast at -$59,283,505 and the highest earnings forecast at -$59,283,505.

What is PRLD's revenue growth forecast for 2030-2030?

(NASDAQ: PRLD) Prelude Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.71%.

Prelude Therapeutics's revenue in 2025 is $0.

In 2030, PRLD is forecast to generate $2,004,347,076 in revenue, with the lowest revenue forecast at $2,004,347,076 and the highest revenue forecast at $2,004,347,076.

What is PRLD's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PRLD) forecast ROA is -39.17%, which is lower than the forecast US Biotechnology industry average of 36.84%.

What is PRLD's Price Target?

According to 2 Wall Street analysts that have issued a 1 year PRLD price target, the average PRLD price target is $4.50, with the highest PRLD stock price forecast at $5.00 and the lowest PRLD stock price forecast at $4.00.

On average, Wall Street analysts predict that Prelude Therapeutics's share price could reach $4.50 by May 5, 2026. The average Prelude Therapeutics stock price prediction forecasts a potential upside of 350% from the current PRLD share price of $1.00.

What is PRLD's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PRLD) Prelude Therapeutics's current Earnings Per Share (EPS) is -$1.69. On average, analysts forecast that PRLD's EPS will be -$1.64 for 2025, with the lowest EPS forecast at -$1.68, and the highest EPS forecast at -$1.59. On average, analysts forecast that PRLD's EPS will be -$1.36 for 2026, with the lowest EPS forecast at -$1.50, and the highest EPS forecast at -$1.21. In 2027, PRLD's EPS is forecast to hit -$1.05 (min: -$1.05, max: -$1.05).

What is PRLD's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PRLD) forecast ROE is -53.63%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.